Edition:
United States

Pain Therapeutics Inc (PTIE.OQ)

PTIE.OQ on NASDAQ Stock Exchange Global Select Market

3.36USD
18 Aug 2017
Change (% chg)

$0.13 (+4.02%)
Prev Close
$3.23
Open
$3.25
Day's High
$3.36
Day's Low
$3.25
Volume
1,107
Avg. Vol
10,597
52-wk High
$21.00
52-wk Low
$3.18

PTIE.OQ

Chart for PTIE.OQ

About

Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a... (more)

Overall

Beta: 2.16
Market Cap(Mil.): $22.16
Shares Outstanding(Mil.): 6.60
Dividend: --
Yield (%): --

Financials

  PTIE.OQ Industry Sector
P/E (TTM): -- 78.89 32.56
EPS (TTM): -1.98 -- --
ROI: -71.40 2.83 14.89
ROE: -71.40 5.09 16.13

BRIEF-Pain Therapeutics reports Q2 loss per share $0.64

* Pain Therapeutics reports Q2 2017 financial results and mid-year corporate update

Aug 09 2017

BRIEF-Pain Therapeutics announces FDA clears investigational new drug application for PTI-125

* Pain Therapeutics announces FDA has cleared an investigational new drug (IND) application for PTI-125

Jul 31 2017

BRIEF-Pain Therapeutics announces reverse stock split

* Pain therapeutics inc - that it will effect a 7-for-1 reverse split of its outstanding shares of common stock effective may 9, 2017 Source text for Eikon: Further company coverage:

May 08 2017

CORRECTED-Durect, Novartis' Sandoz ink deal to develop non-opioid pain drug

May 8 Durect Corp said on Monday it signed an up to $293 million deal with Swiss drugmaker Novartis AG's Sandoz unit to develop and market Durect's experimental non-opioid pain relief therapy, posimir, in the United States.

May 08 2017

BRIEF-Pain Therapeutics reports Q1 loss per share $0.06

* Pain Therapeutics reports first quarter 2017 financial results

Apr 25 2017

BRIEF-Pain Therapeutics announces positive regulatory guidance for Remoxy ER

* Pain Therapeutics announces positive regulatory guidance for Remoxy ER

Mar 20 2017

Competitors

Earnings vs. Estimates